Monte Rosa Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Monte Rosa Therapeutics R&D Spending Growth & History (GLUE)
Monte Rosa Therapeutics's r&d spending was $141.5M for fiscal 2025.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $141.5M | $19.9M | +16.40% |
| 2024 | 2024-12-31 | $121.6M | $10.3M | +9.25% |
| 2023 | 2023-12-31 | $111.3M | $26.2M | +30.81% |
| 2022 | 2022-12-31 | $85.1M | $27.9M | +48.83% |
| 2021 | 2021-12-31 | $57.2M | $33.1M | +138.10% |
| 2020 | 2020-12-31 | $24.0M | — | — |
Monte Rosa Therapeutics quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $48.0M | $17.3M | +56.47% |
| Q1 2026 | 2026-03-31 | $44.1M | $11.9M | +36.90% |
| Q4 2025 | 2025-12-31 | $42.0M | $3.1M | +8.01% |
| Q3 2025 | 2025-09-30 | $36.7M | $9.1M | +32.81% |
| Q2 2025 | 2025-06-30 | $30.7M | $2.6M | +9.26% |
| Q1 2025 | 2025-03-31 | $32.2M | $5.2M | +19.11% |
| Q4 2024 | 2024-12-31 | $38.9M | $11.7M | +43.23% |
| Q3 2024 | 2024-09-30 | $27.6M | −$690,000 | −2.44% |
| Q2 2024 | 2024-06-30 | $28.1M | −$1.0M | −3.51% |
| Q1 2024 | 2024-03-31 | $27.0M | $271,000 | +1.01% |
| Q4 2023 | 2023-12-31 | $27.1M | $2.3M | +9.12% |
| Q3 2023 | 2023-09-30 | $28.3M | $7.0M | +32.63% |
| Q2 2023 | 2023-06-30 | $29.1M | $8.1M | +38.88% |
| Q1 2023 | 2023-03-31 | $26.8M | $8.8M | +49.34% |
| Q4 2022 | 2022-12-31 | $24.9M | $6.7M | +37.16% |
| Q3 2022 | 2022-09-30 | $21.3M | $6.2M | +41.20% |
| Q2 2022 | 2022-06-30 | $20.9M | $6.3M | +43.03% |
| Q1 2022 | 2022-03-31 | $17.9M | $8.6M | +93.20% |
| Q4 2021 | 2021-12-31 | $18.1M | — | — |
| Q3 2021 | 2021-09-30 | $15.1M | $9.6M | +176.22% |
| Q2 2021 | 2021-06-30 | $14.6M | $9.8M | +201.48% |
| Q1 2021 | 2021-03-31 | $9.3M | — | — |
| Q3 2020 | 2020-09-30 | $5.5M | — | — |
| Q2 2020 | 2020-06-30 | $4.9M | — | — |
Monte Rosa Therapeutics r&d spending trends
Over the last five fiscal years, Monte Rosa Therapeutics's r&d spending increased from $24.0M to $141.5M, a change of $117.5M. The latest reported quarter, Q2 2026, shows $48.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics source filings ↗